(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/052846 A2

(51) International Patent Classification:
C07K 16/00 (2006.01) *A61P 37/00* (2006.01)
C07K 14/54 (2006.01) *A61P 35/00* (2006.01)
C07K 14/715 (2006.01) *A61K 39/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/IB2022/000572

(22) International Filing Date:
30 September 2022 (30.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/250,911 30 September 2021 (30.09.2021) US
63/351,298 10 June 2022 (10.06.2022) US

(71) Applicant: **ILDONG PHARMACEUTICAL CO., LTD.** [KR/KR]; 2, Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR).

(72) Inventors: **BAN, Hong Seok**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **YANG, Seok-Woo**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **KWON, Hye Mi**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **CHO, Jea Won**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **SHON, Suh-Youn**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **LEE, Do Sup**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **LEE, Ji-Hyung**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **LEE, Seong Wook**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **SON, Ukjin**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **BAN, Jun Su**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR). **KIM, Jihye**; 2 Baumoe-ro 27-gil, Seocho-gu, Seoul, 06752 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

(54) Title: IMMUNOCYTOKINE CONTAINING IL-21R MUTEIN



Figure 1

(57) Abstract: Provided herein is an immunocytokine comprising (i) an antigen binding protein (ABP) specific to a target protein; (ii) an IL-21 domain; and (iii) an IL-21Rα mutein, wherein the IL-21Rα mutein has a reduced binding affinity to the IL-21 domain compared to a wild-type IL-21Rα. Further provided includes a method of using the immunocytokine to selectively activate an IL-21Rα on a target cell, thereby enhance immune response or treat cancer.

WO 2023/052846 A2

[Continued on next page]

LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*